#Body-on-frameSuvSales

The 2018 Nissan Armada will be priced at $46,795, including destination, when it goes on sale Friday, September 1st; a $700 increase compared with 2016.

While that price increase would have been enough for the Nissan Armada to maintain its position as America’s least costly body-on-frame, full-size SUV, the sudden appearance of the 2018 Chevrolet Tahoe Custom has altered the playing field.

Competitors, not just Nissan but Toyota and Ford as well, didn’t need to give the class-leading Chevrolet even more capacity to dominate the category. But now the best seller is also the bargain of the bunch, and by a noticeable margin.

All across America, Hummer H2s are rolling over in their graves.

What even is a Toyota C-HR? Is the Hyundai Kona an indirect Kia Borrego replacement? The Jeep Renegade shares its platform with… an Italian cute-ute?

But have no fear, dead Hummer. The body-on-frame SUV is here to stay. The surge in crossovers — both the number sold and the number of nameplates available — has not caused the American consumer to leave traditional SUVs behind entirely.

U.S. sales of traditional body-on-frame SUVs are up 7 percent through the first five months of 2017, right on par with the growth rate achieved by the SUV/crossover sector as a whole.

Sales of full-size, body-on-frame, pickup truck-based SUVs from volume brands are up 58% through the first two months of 2015.

The Chevrolet Suburban and Tahoe, GMC Yukon and Yukon XL, Ford Expedition, Nissan Armada, and Toyota Sequoia produced 41,557 sales in January and February, or about the same number as the Toyota RAV4, America’s second-best-selling SUV/CUV. RAV4 sales are up 25%, year-over-year.

Did you know Mercedes still sells the G-Wagen here? I’d kind of forgotten about it. But sixty-eight buyers hadn’t in November. But then I’ve never forgiven Mercedes for how they positioned it here as a gangsta’ mobile. It was/is the ultimate off-roader. Oh well. GM continues to dominate this market with their big boyz. Range Rover looks surprisingly healthy. Did Tata buy low? Details: